MASCC 2025 Highlights: Managing Pulmonary Toxicity from ADCs
@cancercaremascc.bsky.social
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #MASCC #PulmonaryToxicity #ADCs
@cancercaremascc.bsky.social
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #MASCC #PulmonaryToxicity #ADCs
MASCC 2025 Highlights: Pulmonary Toxicity from ADCs
ADCs related pulmonary toxicity, pneumonitis risks, mechanisms, and management strategies across cancer types. MASCC 2025
oncodaily.com
June 28, 2025 at 9:30 PM
MASCC 2025 Highlights: Managing Pulmonary Toxicity from ADCs
@cancercaremascc.bsky.social
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #MASCC #PulmonaryToxicity #ADCs
@cancercaremascc.bsky.social
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #MASCC #PulmonaryToxicity #ADCs
This phase III trial demonstrates that #ARX788 significantly improves #ProgressionFreeSurvival over lapatinib plus capecitabine in #HER2-positive advanced #BreastCancer, showing strong efficacy and manageable ocular and #PulmonaryToxicity.
#OpenAccess #STTT: doi.org/10.1038/s413...
#OpenAccess #STTT: doi.org/10.1038/s413...
November 13, 2025 at 10:00 AM
This phase III trial demonstrates that #ARX788 significantly improves #ProgressionFreeSurvival over lapatinib plus capecitabine in #HER2-positive advanced #BreastCancer, showing strong efficacy and manageable ocular and #PulmonaryToxicity.
#OpenAccess #STTT: doi.org/10.1038/s413...
#OpenAccess #STTT: doi.org/10.1038/s413...